{
}
Deutsche Bank analyst Emmanuel Papadakis upgraded Sanofi's stock from Sell to Hold, raising the price target to €100.00 from €85.00, following strong fourth-quarter results that indicated solid growth and reduced risks. The upgrade reflects improved sentiment towards Sanofi's strategy, particularly with the positive performance of Dupixent in the COPD market, and a clarified buyback program that alleviated merger concerns. Investors may interpret this as a sign of Sanofi's stability and potential for sustained growth.
UBS has increased its target price for Sanofi from 115 to 120 euros while maintaining a "Buy" rating, citing a strong fourth quarter and an impressive share buyback program. Analyst Jo Walton noted high single-digit growth for Dupixent and expressed confidence in the respiratory drug Beyfortus despite competition.
Sanofi, Europe's leading pharmaceutical group, generates 70.6% of its sales from pharmaceutical products, with specialty medicines accounting for 59.3%. The company also focuses on human vaccines (17.4%) and consumer healthcare products (12%). By the end of 2023, Sanofi will operate 54 production sites globally, with significant sales in the United States (43%) and Europe (18.6%).
UBS has raised its target price for Sanofi from 115 to 120 euros, maintaining a "Buy" rating. Analyst Jo Walton noted a strong fourth quarter and an impressive share buyback program, with Dupixent continuing to show high single-digit growth. The company remains optimistic about its respiratory drug Beyfortus despite competition.
UBS has increased its target price for Sanofi from 115 to 120 euros, maintaining a "Buy" rating. Analyst Jo Walton noted a strong fourth quarter and an impressive share buyback program, while highlighting the continued growth of the drug Dupixent and confidence in the respiratory drug Beyfortus despite competition.
UBS has maintained its "Buy" rating for Sanofi, setting a target price of 115 euros. Analyst Jo Walton positively assessed the company's quarterly report, noting that the share buyback program exceeded expectations.
UBS has upgraded SANOFI to a 'Buy' rating, indicating a positive outlook for the stock. However, the information provided is for informational purposes only and does not constitute a recommendation to buy or sell securities. Investors are reminded of the risks involved, including the potential total loss of capital.
Sanofi, Europe's leading pharmaceutical group, generates 70.6% of its sales from pharmaceutical products, with specialty medicines accounting for 59.3%. The company also focuses on human vaccines (17.4%) and consumer healthcare products (12%). By the end of 2023, Sanofi will operate 54 production sites globally, with significant sales in the United States (43%) and Europe (18.6%).
UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 115 euros. Analyst Jo Walton positively assessed the company's quarterly report, noting that the share buyback program exceeded expectations. As of the latest trading, Sanofi shares are priced at approximately 103.12 euros, reflecting a 1.38% increase.
European stocks are set to open higher as investors anticipate a 25-basis-point rate cut from the European Central Bank, bringing the key overnight deposit rate to 2.75%. Key earnings reports are expected from companies including Nokia, Deutsche Bank, and Shell, while market attention will focus on growth data and consumer confidence in the euro zone.
Sanofi
Companies
| Symbol | SNY |
| Name | Sanofi |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Pharmaceuticals |
| Market | NASDAQ Global Select |
| Country | France |
| State | |
| City | Paris |
| Zipcode | 75008 |
| Website | http://www.sanofi.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Deutsche Bank upgrades Sanofi stock to hold with increased price target
13:24 31.01.2025
ubs raises sanofi target price to 120 euros maintains buy rating
11:20 31.01.2025
sanofi's diverse portfolio drives strong sales across global markets
11:07 31.01.2025
ubs raises sanofi target price to 120 euros maintaining buy rating
11:07 31.01.2025
ubs raises sanofi target price to 120 euros maintaining buy rating
10:20 31.01.2025
UBS maintains buy rating for Sanofi with target price of 115 euros
12:43 30.01.2025
ubs upgrades sanofi to buy amid investment considerations and risks
12:43 30.01.2025
sanofi's diverse portfolio drives strong sales across global markets
12:30 30.01.2025
ubs maintains buy rating for sanofi with target price of 115 euros
11:43 30.01.2025
European stocks poised for gains as ECB prepares for rate cut
Euro
Electrolux AB
Shell plc
ABB Ltd
BBVAMRF A
CaixaBank GIF Iberia R
Sanofi
Nordea Bank Abp
Sage Group (The) PLC
Nokia Oyj
WIZZ AIR HLDGS PLC
Hoffmann-La Roche AG
BT Group plc
DEU
AUS
FRA
JPN
ITA
CHN
KOR
GBR
TWN
USA
HKG
Show more
06:34 30.01.2025
Trending
Subcategory
Countries:
Companies:
Currencies:
People: